- 18 mar.- 12:06

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Business Wire.
  • Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease
  • Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2
  • Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni

Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Pianeta Camere

Real Estate

Criptovalute news